← Library
Survodutide
Research Use
Also known as BI 456906
Function
Primary
Obesity · MASH (investigational)
Mechanism
Dual GLP-1 / glucagon receptor agonist — appetite suppression plus hepatic energy expenditure; strong hepatic-fat reduction.
Evidence
Clinical RCT (Limited)
Research
Phase 2 ~19% weight loss; MASH Phase 2 positive
Dosing
Range
0.6–4.8 mg/week (trial)
Frequency
Weekly
Route
Subcutaneous
Cycling
Continuous, stepwise titration.
Benefits
- ·Weight loss
- ·MASH/MASLD resolution
- ·Improved liver enzymes
Risks
- ·GI intolerance
- ·Heart rate increase
- ·Hyperglycemia risk via glucagon arm
Contraindications
- ·MTC / MEN-2 (class)
- ·Pregnancy
Regulatory
Investigational (Boehringer Ingelheim / Zealand, Phase 3)
Functional Groups
Cited Works
- le Roux CW et al. Survodutide for Obesity — Phase 2 RCT. N Engl J Med. 2024;391:719.source